Skip to main content

Why obesity drug coverage doesn't matter (yet) for Lilly and Novo

By The Wall Street Journal  
   January 31, 2024

Makers of Wegovy, Ozempic and Zepbound can't keep up with demand for their GLP-1 drugs, so insurance coverage isn't important for near-term growth.

Full story


Get the latest on healthcare leadership in your inbox.